Inify Laboratories: Progress in the dialogue with NHS in the UK and continued growth in Sweden
STOCKHOLM - April 29, 2026 - Inify Laboratories, a unique laboratory service that provides cancer diagnostics within pathology, today announces significant progress in its UK market entry and continued sales growth in Sweden during the first quarter.
Sales increased compared to the same period last year, with the company's Swedish subsidiary delivering positive results for the sixth consecutive quarter. At the same time, Inify has made important progress in the UK through advancing discussions with the NHS at both national and hospital levels.
"We are very encouraged by the progress we are making with the NHS," said Fredrik Palm, CEO of Inify Laboratories. "Entering the UK public healthcare system is a complex process, but we are now engaged in concrete contract discussions, which is a clear sign that our offering is gaining traction."
Advancing towards UK operational start
During the quarter, Inify initiated contract discussions with NHS stakeholders regarding staged, funded evaluation projects. These evaluations are designed to assess performance within existing care pathways before gradually transitioning to Inify's diagnostic services.
The company expects to begin receiving its first patient samples from the UK in June. The laboratory in the UK is fully equipped and technically verified, and regulatory approval for routine clinical operations is anticipated in the second quarter.
"While the timeline is slightly later than originally planned, it aligns well with when we expect to start receiving patient samples," added Palm. "Each step in this process strengthens our position and supports the path to broader implementation."
Continued growth in Sweden
In Sweden, Inify continues to demonstrate strong operational and commercial momentum. The company's laboratory has now achieved six consecutive quarters of positive results, supported by increasing demand for its prostate cancer diagnostics services.
Growth forward is primarily expected to come from the public healthcare sector, where Inify recently began receiving patient samples as part of a new regional evaluation project. The company also reports several ongoing dialogues with additional regions.
"Our Swedish operations clearly demonstrate the value we bring," said Palm. "We are seeing both increased volumes of samples in the laboratory and tangible improvements for healthcare providers, including shorter turnaround times and enhanced workflow."
Official statistics shows that regions that are sending their patient samples to Inify has reduced the waiting times for results to patient by several weeks, while also enabling new, more efficient ways of working across the patient pathway.
In addition to its prostate cancer diagnostics offering, Inify recently received extended ISO 15189 accreditation for gastrointestinal diagnostics, opening new avenues for growth with both private and public healthcare providers.
"Next major step not a question of if - but when"
Following a successful share issue completed in March, Inify has strengthened its financial position to support continued expansion, particularly in the UK market.
"We are in a phase where persistence and execution are key," Palm concluded. "The demand for efficient, higher-quality diagnostics is clear. With a strong foundation in Sweden and meaningful progress in the UK, it is not a question of if - but when - we take the next major step in our growth journey."
For further information, please contact CEO, Fredrik Palm, fredrik.palm@inify.com, or visit https://www.inify.com
###
This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act.
###
The future of diagnostics
Inify Laboratories offers diagnostics through specialised laboratory services in histopathology, with a focus on streamlining patient pathways. The company performs clinical diagnostics in prostate cancer and gastroenterology, providing an integrated service that spans from early sample handling to final diagnosis. The laboratory system is scalable both in handling large volumes of patient samples and for replicating in new locations.
Quality and response times are optimised in every step - from logistics to tissue preparation and diagnosis - using a fully digital, standardised and AI -assisted workflow. The diagnosis is always performed by a pathologist and is assisted by Inify's proprietary AI, proven to have world-leading precision in clinical evaluations. The entire workflow is supported by a tailor-made system that also enables development to include additional diagnostic areas.
Inify Laboratories is an international group headquartered in Stockholm, Sweden, with local laboratories in Sweden and the UK. The company's share is listed on Euronext Growth Oslo (https://live.euronext.com/en/product/equities/SE0017486103 -MERK) under the ticker INIFY. (https://live.euronext.com/en/product/equities/SE0017486103-MERK)